Treatment of psoriatic arthritis with traditional DMARD's and novel therapies: approaches and recommendations.

about

Treatment of psoriatic arthritis with traditional DMARD's and novel therapies: approaches and recommendations.

Item

http://www.wikidata.org/entity/Q39003610

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

Treatment of psoriatic arthrit ...... pproaches and recommendations.

@en

Treatment of psoriatic arthrit ...... pproaches and recommendations.

@nl

type

Item

label

Treatment of psoriatic arthrit ...... pproaches and recommendations.

@en

Treatment of psoriatic arthrit ...... pproaches and recommendations.

@nl

prefLabel

Treatment of psoriatic arthrit ...... pproaches and recommendations.

@en

Treatment of psoriatic arthrit ...... pproaches and recommendations.

@nl

P1476

Treatment of psoriatic arthrit ...... approaches and recommendations

@en

P2093

Ajesh B Maharaj

http://www.w3.org/2001/XMLSchema#string

Vinod Chandran

http://www.w3.org/2001/XMLSchema#string

P2860

Circulating Th17, Th22, and Th1 cells are increased in psoriasis

Mast cells and neutrophils release IL-17 through extracellular trap formation in psoriasis

Adalimumab for long-term treatment of psoriatic arthritis: forty-eight week data from the adalimumab effectiveness in psoriatic arthritis trial.

Adalimumab for long-term treatment of psoriatic arthritis: 2-year data from the Adalimumab Effectiveness in Psoriatic Arthritis Trial (ADEPT)

Cyclosporin A in psoriatic arthritis: an open study.

Treatment of psoriatic arthritis in a phase 3 randomised, placebo-controlled trial with apremilast, an oral phosphodiesterase 4 inhibitor.

Weight loss and achievement of minimal disease activity in patients with psoriatic arthritis starting treatment with tumour necrosis factor α blockers.

Efficacy and safety of the anti-IL-12/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional non-biological and biological anti-tumour necrosis factor therapy: 6-month and 1-year results of the phas

Head-to-head, randomised, crossover study of oral versus subcutaneous methotrexate in patients with rheumatoid arthritis: drug-exposure limitations of oral methotrexate at doses ≥15 mg may be overcome with subcutaneous administration.

Clinical efficacy, radiographic and safety findings through 5 years of subcutaneous golimumab treatment in patients with active psoriatic arthritis: results from a long-term extension of a randomised, placebo-controlled trial (the GO-REVEAL study).

P304

319-331

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1080/1744666X.2017.1257939

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Ajesh Basantharan Maharaj

Vinod Chandran

P577

2016-11-18T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27826996

http://www.w3.org/2001/XMLSchema#string